Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Next Previous
Trial Profile

A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozagrel (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Kissei Pharmaceutical

Most Recent Events

  • 24 Apr 2017 According to a company media release, since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug, Kissei cautiously discussed a future development policy with Teika and has decided to discontinue the development of this drug.
  • 24 Apr 2017 Status changed from recruiting to discontinued, according to a Kissei Pharmaceuticals media release.
  • 22 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top